{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:14:41Z","timestamp":1793873681375,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Frederick Banting and Charles Best Canada Graduate Scholarship"},{"name":"Biomedical summer student scholarship from the College of Medicine, University of Saskatchewan"},{"DOI":"10.13039\/100017294","name":"Saskatchewan Cancer Agency","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017294","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008920","name":"University of Saskatchewan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008920","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The lack of targeted therapies for triple-negative breast cancer (TNBC) contributes to their high mortality rates and high risk of relapse compared to other subtypes of breast cancer. Most TNBCs (75%) have downregulated the expression of CREB3L1 (cAMP-responsive element binding protein 3 like 1), a transcription factor and metastasis suppressor that represses genes that promote cancer progression and metastasis. In this report, we screened an FDA-approved drug library and identified four drugs that were highly cytotoxic towards HCC1806 CREB3L1-deficient TNBC cells. These four drugs were: (1) palbociclib isethionate, a CDK4\/6 inhibitor, (2) lanatocide C (also named isolanid), a Na+\/K+-ATPase inhibitor, (3) cladribine, a nucleoside analog, and (4) homoharringtonine (also named omacetaxine mepesuccinate), a protein translation inhibitor. Homoharringtonine consistently showed the most cytotoxicity towards an additional six TNBC cell lines (BT549, HCC1395, HCC38, Hs578T, MDA-MB-157, MDA-MB-436), and several luminal A breast cancer cell lines (HCC1428, MCF7, T47D, ZR-75-1). All four drugs were then separately evaluated for possible synergy with the chemotherapy agents, doxorubicin (an anthracycline) and paclitaxel (a microtubule stabilizing agent). A strong synergy was observed using the combination of homoharringtonine and paclitaxel, with high cytotoxicity towards TNBC cells at lower concentrations than when each was used separately.<\/jats:p>","DOI":"10.1038\/s41598-022-19621-7","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T13:04:16Z","timestamp":1663592656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel"],"prefix":"10.1038","volume":"12","author":[{"given":"Riley","family":"Plett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Austin","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aren","family":"Boulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Vizeacoumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco J.","family":"Vizeacoumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah H.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"19621_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"19621_CR2","unstructured":"Website, G. O. C.-P. H. Breast Cancer, http:\/\/www.phac-aspc.gc.ca\/cd-mc\/cancer\/breast_cancer-cancer_du_sein-eng.php (2015)."},{"key":"19621_CR3","unstructured":"Society, A. C. Breast Cancer Survival Rates, by Stage, http:\/\/www.cancer.org\/cancer\/breastcancer\/detailedguide\/breast-cancer-survival-by-stage (2016)."},{"key":"19621_CR4","unstructured":"Society, C. C. Breast Cancer Statistics, https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/breast\/statistics?_ga=2.263777804.1429687422.1641410797-1677001365.1619734808> (2020)."},{"key":"19621_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","volume":"38","author":"P Eroles","year":"2012","unstructured":"Eroles, P., Bosch, A., Perez-Fidalgo, J. A. & Lluch, A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 38, 698\u2013707. https:\/\/doi.org\/10.1016\/j.ctrv.2011.11.005 (2012).","journal-title":"Cancer Treat. Rev."},{"key":"19621_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4137\/BCBCR.S9454","volume":"8","author":"MM Rampurwala","year":"2014","unstructured":"Rampurwala, M. M., Rocque, G. B. & Burkard, M. E. Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl.) 8, 125\u2013133. https:\/\/doi.org\/10.4137\/BCBCR.S9454 (2014).","journal-title":"Breast Cancer (Auckl.)"},{"key":"19621_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2045-3701-1-6","volume":"1","author":"CP Chan","year":"2011","unstructured":"Chan, C. P., Kok, K. H. & Jin, D. Y. CREB3 subfamily transcription factors are not created equal: Recent insights from global analyses and animal models. Cell Biosci. 1, 6. https:\/\/doi.org\/10.1186\/2045-3701-1-6 (2011).","journal-title":"Cell Biosci."},{"key":"19621_CR8","doi-asserted-by":"publisher","first-page":"10271","DOI":"10.1074\/jbc.REV120.012669","volume":"295","author":"J Ye","year":"2020","unstructured":"Ye, J. Transcription factors activated through RIP (regulated intramembrane proteolysis) and RAT (regulated alternative translocation). J. Biol. Chem. 295, 10271\u201310280. https:\/\/doi.org\/10.1074\/jbc.REV120.012669 (2020).","journal-title":"J. Biol. Chem."},{"key":"19621_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fcell.2019.00123","volume":"7","author":"L Sampieri","year":"2019","unstructured":"Sampieri, L., Di Giusto, P. & Alvarez, C. CREB3 transcription factors: ER-golgi stress transducers as hubs for cellular homeostasis. Front. Cell Dev. Biol 7, 123. https:\/\/doi.org\/10.3389\/fcell.2019.00123 (2019).","journal-title":"Front. Cell Dev. Biol"},{"key":"19621_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12565-013-0214-x","volume":"89","author":"A Saito","year":"2014","unstructured":"Saito, A. Physiological functions of endoplasmic reticulum stress transducer OASIS in central nervous system. Anat. Sci. Int. 89, 11\u201320. https:\/\/doi.org\/10.1007\/s12565-013-0214-x (2014).","journal-title":"Anat. Sci. Int."},{"key":"19621_CR11","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1128\/MCB.00959-13","volume":"33","author":"P Mellor","year":"2013","unstructured":"Mellor, P. et al. CREB3L1 is a metastasis suppressor that represses expression of genes regulating metastasis, invasion and angiogenesis. Mol. Cell Biol. 33, 4985\u20134995. https:\/\/doi.org\/10.1128\/MCB.00959-13 (2013).","journal-title":"Mol. Cell Biol."},{"key":"19621_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13058-016-0672-x","volume":"18","author":"AK Ward","year":"2016","unstructured":"Ward, A. K. et al. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers. Breast Cancer Res. 18, 12. https:\/\/doi.org\/10.1186\/s13058-016-0672-x (2016).","journal-title":"Breast Cancer Res."},{"key":"19621_CR13","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.4161\/15592294.2014.988052","volume":"9","author":"M Rose","year":"2014","unstructured":"Rose, M. et al. OASIS\/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro. Epigenetics 9, 1626\u20131640. https:\/\/doi.org\/10.4161\/15592294.2014.988052 (2014).","journal-title":"Epigenetics"},{"key":"19621_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12885-018-4724-8","volume":"18","author":"B Denard","year":"2018","unstructured":"Denard, B., Jiang, S., Peng, Y. & Ye, J. CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy. BMC Cancer 18, 813. https:\/\/doi.org\/10.1186\/s12885-018-4724-8 (2018).","journal-title":"BMC Cancer"},{"key":"19621_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271090","volume":"17","author":"P Mellor","year":"2022","unstructured":"Mellor, P., Kendall, S., Smith, S., Saxena, A. & Anderson, D. H. Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis. PLoS ONE 17, e0271090. https:\/\/doi.org\/10.1371\/journal.pone.0271090 (2022).","journal-title":"PLoS ONE"},{"key":"19621_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/msb.2013.54","volume":"9","author":"FJ Vizeacoumar","year":"2013","unstructured":"Vizeacoumar, F. J. et al. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol. Syst. Biol. 9, 696. https:\/\/doi.org\/10.1038\/msb.2013.54 (2013).","journal-title":"Mol. Syst. Biol."},{"key":"19621_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006752","volume":"15","author":"A Malyutina","year":"2019","unstructured":"Malyutina, A. et al. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput. Biol. 15, e1006752. https:\/\/doi.org\/10.1371\/journal.pcbi.1006752 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"19621_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","volume":"1711","author":"L He","year":"2018","unstructured":"He, L. et al. Methods for high-throughput drug combination screening and synergy scoring. Methods Mol. Biol. 1711, 351\u2013398. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_17 (2018).","journal-title":"Methods Mol. Biol."},{"key":"19621_CR19","doi-asserted-by":"publisher","first-page":"13942","DOI":"10.18632\/oncotarget.14572","volume":"8","author":"C Zhao","year":"2017","unstructured":"Zhao, C. et al. Repurposing an antidandruff agent to treating cancer: Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. Oncotarget 8, 13942\u201313956. https:\/\/doi.org\/10.18632\/oncotarget.14572 (2017).","journal-title":"Oncotarget"},{"key":"19621_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513. https:\/\/doi.org\/10.1016\/j.csbj.2015.09.001 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"19621_CR21","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427\u20131438 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"19621_CR22","doi-asserted-by":"publisher","first-page":"175883591881834","DOI":"10.1177\/1758835918818346","volume":"10","author":"A Matutino","year":"2018","unstructured":"Matutino, A., Amaro, C. & Verma, S. CDK4\/6 inhibitors in breast cancer: Beyond hormone receptor-positive HER2-negative disease. Ther. Adv. Med. Oncol. 10, 1758835918818346. https:\/\/doi.org\/10.1177\/1758835918818346 (2018).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"19621_CR23","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370. https:\/\/doi.org\/10.1038\/nature11412 (2012).","DOI":"10.1038\/nature11412"},{"key":"19621_CR24","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","volume":"48","author":"PL Toogood","year":"2005","unstructured":"Toogood, P. L. et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6. J. Med. Chem. 48, 2388\u20132406. https:\/\/doi.org\/10.1021\/jm049354h (2005).","journal-title":"J. Med. Chem."},{"key":"19621_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s1535-6108(02)00102-2","volume":"2","author":"CJ Sherr","year":"2002","unstructured":"Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103\u2013112. https:\/\/doi.org\/10.1016\/s1535-6108(02)00102-2 (2002).","journal-title":"Cancer Cell"},{"key":"19621_CR26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele, A. et al. CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: Phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 21, 995\u20131001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2258 (2015).","journal-title":"Clin. Cancer Res."},{"key":"19621_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/cas.13841","volume":"110","author":"M Harada","year":"2019","unstructured":"Harada, M. et al. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer. Cancer Sci. 110, 209\u2013220. https:\/\/doi.org\/10.1111\/cas.13841 (2019).","journal-title":"Cancer Sci."},{"key":"19621_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/biom9120792","volume":"9","author":"D Reddy","year":"2019","unstructured":"Reddy, D., Kumavath, R., Ghosh, P. & Barh, D. Lanatoside C induces G2\/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K\/AKT\/mTOR signaling pathways. Biomolecules 9, 5. https:\/\/doi.org\/10.3390\/biom9120792 (2019).","journal-title":"Biomolecules"},{"key":"19621_CR29","doi-asserted-by":"publisher","first-page":"46134","DOI":"10.1038\/srep46134","volume":"7","author":"MW Chao","year":"2017","unstructured":"Chao, M. W. et al. Lanatoside C, a cardiac glycoside, acts through protein kinase Cdelta to cause apoptosis of human hepatocellular carcinoma cells. Sci. Rep. 7, 46134. https:\/\/doi.org\/10.1038\/srep46134 (2017).","journal-title":"Sci. Rep."},{"key":"19621_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","volume":"322","author":"LD Piro","year":"1990","unstructured":"Piro, L. D., Carrera, C. J., Carson, D. A. & Beutler, E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 322, 1117\u20131121. https:\/\/doi.org\/10.1056\/NEJM199004193221605 (1990).","journal-title":"N. Engl. J. Med."},{"key":"19621_CR31","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","volume":"116","author":"DS Sigal","year":"2010","unstructured":"Sigal, D. S., Miller, H. J., Schram, E. D. & Saven, A. Beyond hairy cell: The activity of cladribine in other hematologic malignancies. Blood 116, 2884\u20132896. https:\/\/doi.org\/10.1182\/blood-2010-02-246140 (2010).","journal-title":"Blood"},{"key":"19621_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers10070240","volume":"10","author":"N Tsesmetzis","year":"2018","unstructured":"Tsesmetzis, N., Paulin, C. B. J., Rudd, S. G. & Herold, N. Nucleobase and nucleoside analogues: Resistance and re-sensitisation at the level of pharmacokinetics. Pharmacodyn. Metabol. Cancers 10, 240. https:\/\/doi.org\/10.3390\/cancers10070240 (2018).","journal-title":"Pharmacodyn. Metabol. Cancers"},{"key":"19621_CR33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s10549-011-1477-3","volume":"131","author":"EJ Geutjes","year":"2012","unstructured":"Geutjes, E. J., Tian, S., Roepman, P. & Bernards, R. Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res. Treat. 131, 809\u2013818. https:\/\/doi.org\/10.1007\/s10549-011-1477-3 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"19621_CR34","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/1042819031000099698","volume":"44","author":"K Lotfi","year":"2003","unstructured":"Lotfi, K., Juliusson, G. & Albertioni, F. Pharmacological basis for cladribine resistance. Leuk. Lymphoma 44, 1705\u20131712. https:\/\/doi.org\/10.1080\/1042819031000099698 (2003).","journal-title":"Leuk. Lymphoma"},{"key":"19621_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3892\/etm.2019.7601","volume":"18","author":"C Wu","year":"2019","unstructured":"Wu, C., Zhao, A., Tan, T., Wang, Y. & Shen, Z. Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD. Exp. Ther. Med. 18, 550\u2013558. https:\/\/doi.org\/10.3892\/etm.2019.7601 (2019).","journal-title":"Exp. Ther. Med."},{"key":"19621_CR36","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/cdd.2015.73","volume":"22","author":"CM Goodwin","year":"2015","unstructured":"Goodwin, C. M., Rossanese, O. W., Olejniczak, E. T. & Fesik, S. W. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 22, 2098\u20132106. https:\/\/doi.org\/10.1038\/cdd.2015.73 (2015).","journal-title":"Cell Death Differ."},{"key":"19621_CR37","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905. https:\/\/doi.org\/10.1038\/nature08822 (2010).","journal-title":"Nature"},{"key":"19621_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","volume":"4","author":"JM Balko","year":"2014","unstructured":"Balko, J. M. et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 4, 232\u2013245. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0286 (2014).","journal-title":"Cancer Discov."},{"key":"19621_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41419-017-0035-2","volume":"9","author":"KJ Campbell","year":"2018","unstructured":"Campbell, K. J. et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 9, 19. https:\/\/doi.org\/10.1038\/s41419-017-0035-2 (2018).","journal-title":"Cell Death Dis."},{"key":"19621_CR40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/scitranslmed.aam7049","volume":"9","author":"D Merino","year":"2017","unstructured":"Merino, D. et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci. Transl. Med. 9, 401. https:\/\/doi.org\/10.1126\/scitranslmed.aam7049 (2017).","journal-title":"Sci. Transl. Med."},{"key":"19621_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13058-016-0781-6","volume":"18","author":"AI Young","year":"2016","unstructured":"Young, A. I. et al. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Res. 18, 125. https:\/\/doi.org\/10.1186\/s13058-016-0781-6 (2016).","journal-title":"Breast Cancer Res."},{"key":"19621_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jmb.2009.04.005","volume":"389","author":"G Gurel","year":"2009","unstructured":"Gurel, G., Blaha, G., Moore, P. B. & Steitz, T. A. U2504 determines the species specificity of the A-site cleft antibiotics: The structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J. Mol. Biol. 389, 146\u2013156. https:\/\/doi.org\/10.1016\/j.jmb.2009.04.005 (2009).","journal-title":"J. Mol. Biol."},{"key":"19621_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-7-2","volume":"7","author":"S Lu","year":"2014","unstructured":"Lu, S. & Wang, J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J. Hematol. Oncol. 7, 2. https:\/\/doi.org\/10.1186\/1756-8722-7-2 (2014).","journal-title":"J. Hematol. Oncol."},{"key":"19621_CR44","first-page":"1043","volume":"9","author":"M Yakhni","year":"2019","unstructured":"Yakhni, M. et al. Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance. Am. J. Cancer Res. 9, 1043\u20131060 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"19621_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ccr.2013.07.008","volume":"24","author":"F Petrocca","year":"2013","unstructured":"Petrocca, F. et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 24, 182\u2013196. https:\/\/doi.org\/10.1016\/j.ccr.2013.07.008 (2013).","journal-title":"Cancer Cell"},{"key":"19621_CR46","first-page":"96S","volume":"17","author":"RT Dorr","year":"1997","unstructured":"Dorr, R. T. Pharmacology of the taxanes. Pharmacotherapy 17, 96S-104S (1997).","journal-title":"Pharmacotherapy"},{"key":"19621_CR47","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.E14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver, B. A. How Taxol\/paclitaxel kills cancer cells. Mol. Biol. Cell 25, 2677\u20132681. https:\/\/doi.org\/10.1091\/mbc.E14-04-0916 (2014).","journal-title":"Mol. Biol. Cell"},{"key":"19621_CR48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.21037\/atm-22-1459","volume":"10","author":"F Yuan","year":"2022","unstructured":"Yuan, F., Li, D., Li, G., Cheng, C. & Wei, X. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms. Ann. Transl. Med. 10, 490. https:\/\/doi.org\/10.21037\/atm-22-1459 (2022).","journal-title":"Ann. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19621-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T13:10:22Z","timestamp":1663593022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19621-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19621"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19621-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"3 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15663"}}